Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine

Authors :: Andrés Cervantes
Fortunato Ciardiello
F. De Vita
Valentina Gambardella
A. Diana
Angelica Petrillo
B. Savastano
Maria Maddalena Laterza
Teresa Troiani
Antonio Febbraro
Marisol Huerta
Luca Pompella
Jole Ventriglia
Giuseppe Tirino
Michele Orditura
Source :: Annals of Oncology. 27:vi233
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Internal medicine
Metastatic pancreatic cancer
medicine
Hematology
Neutrophil to lymphocyte ratio
business
Gemcitabine
medicine.drug
Nab-paclitaxel

Tools